In Brief: FDA's Dental Products Panel Plaque Subcommittee
This article was originally published in The Tan Sheet
Executive Summary
FDA's Dental Products Panel Plaque Subcommittee: Will meet Oct. 29-30 from 8:30 a.m. to 5 p.m. at the Holiday Inn, Gaithersburg, Md. On Oct. 29, the committee will continue its discussion of, and may vote on, the safety and effectiveness of C31-G xylitol and zinc citrate, as well as combinations including: menthol/thymol/eucalyptol/menthol salicylate; hydrogen peroxide/povidone-iodine; hydrogen peroxide/sodium citrate; and zinc chloride/sodium lauryl sulfate. The committee also will continue its discussion of the criteria for OTC antiplaque and antigingivitis combination drug products. On Oct. 30, the committee will address final formulation testing for antiplaque/antigingivitis products, and will receive assignments for the review of foreign marketing data supporting antiplaque and antigingivitis ingredients. The subcommittee last discussed these issues in May ("The Tan Sheet" May 12, pp. 4-7)...